Pembrolizumab for Sarcoma
This trial is testing whether the drug pembrolizumab, when combined with two other chemotherapy drugs and delivered directly to an arm or leg, can safely delay disease progression.
- Pleomorphic Sarcoma
- Alveolar Soft Part Sarcoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 3 trial • 453 Patients • NCT03066778
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the sample size of this research endeavor?
"Affirmative. Data available on clinicaltrials.gov confirm that this trial is currently recruiting participants, with the initial posting occurring on April 1st 2020 and most recent update taking place November 21st 2022. The research team needs to enlist around 30 individuals from 10 distinct medical facilities."
Are there any historical precedents of utilizing Pembrolizumab in clinical experiments?
"Discovered in 1997 by City of Hope Comprehensive Cancer Center, pembrolizumab has gone through 482 clinical trials. Currently 1083 live studies are being conducted with a sizable cohort located in Harrison, New York."
Are there any vacancies for potential participants in this medical experiment?
"The investigation, whose initial advertisement went up on the 1st of April 2020 is still seeking participants. Information featured on clinicaltrials.gov was recently updated on November 21 2022."
What risk factors are associated with Pembrolizumab treatments?
"Due to the Phase 2 status of this clinical trial, our team assigns Pembrolizumab a score of two - reflecting prior data supporting its safety but not efficacy."
In what geographic areas is the investigation currently taking place?
"Ten trial sites are enrolling patients, with two of the most notable being Memorial Sloan Kettering Westchester (Limited Protocol Activities) in Harrison and Memorial Sloan Kettering Basking Ridge (Limited protocol activities) in Basking Ridge. Eight other locations have also been approved for patient recruitment."